Physician profile
Kellye L Tapp
NPI 1972540276
$5,955.06
in general payments reported to CMS, 2019-2025
34 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $613 · 2023: $1,134 · 2024: $1,776 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,518 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,518.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.73 | 2021-2025 | |
| Novo Nordisk INC | $724.60 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $616.91 | 2021-2025 | |
| Lilly USA, LLC | $459.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $411.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $267.81 | 2021-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $249.91 | 2021-2025 | |
| Exact Sciences Corporation | $183.19 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.74 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $151.53 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $146.96 | 2021-2023 | Spravato |
| Axsome Therapeutics, INC. | $130.12 | 2025 | Symbravo, Auvelity |
| Phathom Pharmaceuticals, INC. | $122.56 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.37 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $67.97 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.04 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $51.57 | 2021-2024 | Eliquis |
| Amarin Pharma, INC. | $50.11 | 2021 | |
| Mannkind Corporation | $49.54 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.16 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $47.46 | 2023-2024 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $40.84 | 2022-2024 | Gardasil 9, Gardasil, Vaxelis |
| Idorsia Pharmaceuticals US INC | $33.57 | 2023 | Quviviq |
| Lundbeck LLC | $30.80 | 2024-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $24.01 | 2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $23.15 | 2021 | |
| Nevro Corp. | $20.63 | 2023 | Senza |
| Astellas Pharma US INC | $20.58 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $18.76 | 2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $17.41 | 2022 | |
| Neurocrine Biosciences, INC. | $14.58 | 2024 | Ingrezza |
| Emmaus Medical, INC. | $13.89 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.25 | 2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellye Tapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.